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ABSTRACT
Foot-and-mouth disease (FMD) is a highly contagious viral disease affecting biungulate species. Commercial vaccines, formu-
lated with inactivated FMD virus (FMDV), are regularly used worldwide to control the disease. Here, we studied the generation
of antibody responses in local lymphoid tissues along the respiratory system in vaccinated and further aerosol-infected cattle.
Animals immunized with a high-payload monovalent FMD vaccine developed high titers of neutralizing antibodies at 7 days
postvaccination (dpv), reaching a plateau at 29 dpv. FMDV-specific antibody-secreting cells (ASC), predominantly IgM, were
evident at 7 dpv in the prescapular lymph node (LN) draining the vaccination site and in distal LN draining the respiratory mu-
cosa, although in lower numbers. At 29 dpv, a significant switch to IgG1 was clear in prescapular LN, while FMDV-specific ASC
were detected in all lymphoid tissues draining the respiratory tract, mostly as IgM-secreting cells. None of the animals (n  10)
exhibited FMD symptoms after oronasal challenge at 30 dpv. Three days postinfection, a large increase in ASC numbers and
rapid isotype switches to IgG1 were observed, particularly in LN-draining virus replication sites already described. These results
indicate for the first time that systemic FMD vaccination in cattle effectively promotes the presence of anti-FMDV ASC in lym-
phoid tissues associated with the respiratory system. Oronasal infection triggered an immune reaction compatible with a local
anamnestic response upon contact with the replicating FMDV, suggesting that FMD vaccination induces the circulation of virus-
specific B lymphocytes, including memory B cells that differentiate into ASC soon after contact with the infective virus.
IMPORTANCE
Over recent decades, world animal health organizations as well as national sanitary authorities have supported the use of vacci-
nation as an essential component of the official FMD control programs in both endemic and disease-free settings. Very few
works studied the local immunity induced by FMD vaccines at the respiratory mucosa, and local responses induced in vaccinated
animals after aerosol infection have not been described yet. In this work, we demonstrate for the first time that systemic FMD
vaccination (i) induced the early presence of active antigen-specific ASC along the respiratory tract and (ii) prompted a rapid
local antibody response in the respiratory mucosa, triggered upon oronasal challenge and congruent with a memory B-cell re-
sponse. This information may help to understand novel aspects of protective responses induced by current FMD vaccines as well
as to provide alternative parameters to establish protection efficiency for new vaccine developments.
Foot-and-mouth disease (FMD) is a highly contagious andacute viral disease affecting a wide range of economically im-
portant livestock species (1). All domestic biungulates are suscep-
tible to infection with the FMD virus (FMDV); in addition, a
number of wildlife species may act as reservoirs for the virus under
particular ecological conditions (2). Lethality has been described
for young animals and certain FMDV strains (3). However, the
main disruptive potential of this transboundary disease is the high
morbidity rate and the numerous indirect losses associated with
its incursions into territories with susceptible populations. Con-
sequently, FMD outbreaks may result in severe and far-reaching
economic losses due to the interruption of regional and interna-
tional trade in developed countries (4, 5), but also importantly,
due to the loss of animals, production efficiency, and genetic di-
versity in developing regions (6).
Cattle are highly susceptible to FMDV, and virus usually gains
entry through the respiratory tract of the animals (3). The soft
palate and pharynx were identified as primary sites of FMDV rep-
lication and persistence in bovines infected through the oronasal
route (7, 8). FMDV infection progresses through replication in
pneumocytes, permitting the virus to accomplish an extensive dis-
tribution in the lungs which in turn allows the establishment of a
sustained viremia (9).
Disease outbreaks are managed using a spectrum of possible
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strategies, including vaccination and/or the sacrifice of infected
and exposed animals. Starting in the early 2000s, however, several
social, environmental, and economic concerns were raised by the
scientific community and public opinion regarding approaches
involving mass culling of livestock and favoring the use of FMD
vaccination as a control measure (10, 11). Currently, vaccination
is used in both disease-free settings and those where the virus is
endemic around the world, and it is recognized as an essential tool
throughout the FMD Progressive Control Pathway (PCP), en-
dorsed by the Food and Agriculture Organization of the United
Nations (FAO) and the World Organization for Animal Health
(OIE) (12).
Commercial FMD vaccines are based on chemically inacti-
vated whole-virus particles, manufactured as aqueous or oil for-
mulations, formulated with aluminum hydroxide/saponin, or as
single or double emulsions for oil adjuvants (13). During the last
several decades, extensive use of FMD vaccines has prevented the
development and transmission of the disease, as well as decreased
the incidence of persistently infected animals (14–16). Protection
against the disease is closely related to the induction of specific
antibodies (17), and humoral responses generated by FMD vac-
cines are serotype restricted and, in some cases, even strain specific
(13).
The vast majority of studies examining the induction of anti-
bodies in response to FMD vaccination has been at the systemic
level. Despite the importance of understanding the local antibody
response against the virus within the respiratory mucosa, there are
practically no reports addressing the mucosal responses induced
by FMD vaccination in cattle, except for two early reports working
with oronasal secretions (18, 19).
Following our previous study on the induction of local adap-
tive responses in naive bovines infected through the oronasal
route (20), here we analyzed the local antibody production in-
duced after systemic FMD vaccination and the responses triggered
in these animals after oronasal challenge with virulent FMDV.
Our results demonstrate that soon after systemic immunization
with high-payload FMD vaccines, it is possible to detect virus-
specific antibody-secreting cells (ASC) in lymphoid tissues distal
from the inoculation spot. This phenomenon was extended and
enhanced at 29 dpv, observing a progression and dynamics which
differed from those of the FMDV-specific systemic antibody re-
sponses and from the lymph node draining the vaccination site.
Furthermore, oronasal infection with virulent FMDV did not pro-
duce disease in vaccinated steers, characterized by an immune
response that included a rapid isotype switch in lymphoid tissues
located along the entire respiratory tract, which, for some lymph
nodes, occurred simultaneously with an IgM-driven virus-specific
response. Here, we discuss possible mechanisms associated with
these findings, analyze their role in pathogenesis during aeroge-
nous FMDV infection, and compare immune responses at distal
sites with the concurrent antibody responses observed in the vac-
cine-draining lymph tissues and at the systemic level.
MATERIALS AND METHODS
Experimental animals. A total of 16 14- to 18-month-old Hereford steers
were purchased from a livestock breeder located in an FMDV-free region
without vaccination in Argentina (Patagonia). All of the animals were
checked for the absence of FMDV-specific antibodies by liquid-phase
blocking enzyme-linked immunosorbent assay (LPB-ELISA) (21) before
their arrival. Three additional 18- to 20-month-old steers from the exper-
imental field of CICVyA–INTA, which have received three FMD vaccina-
tions (every 6 months) in the frame of the official FMD vaccination cam-
paigns in Argentina, also were utilized in B-cell memory and viral antigen
detection experiments.
Trials which did not include infected bovines were carried out at bio-
safety level 2 (BSL-2) facilities, while experiments with infected cattle were
performed in BSL-4 OIE animal boxes, both located at the CICVyA–
INTA. All experiments were completed by following biosecurity and an-
imal welfare internal and federal regulations and according to protocols
05/2010, 25/2013, and 20/2014, approved by the Institutional Committee
for Use and Care of Experimental Animals (CICUAE), CICVyA–INTA.
Virus, controlled aerosol infection, and clinical assessment in cattle.
Virulent FMDV strain O1/Campos/Brazil/58 (O1 Campos) was provided
by the OIE FMD Reference Laboratory at SENASA, Argentina. Experi-
mental infections through the oronasal route were performed with a jet
nebulizer attached to an aerosol delivery system (107 50% tissue culture
infective doses [TCID50] in a 2-ml volume per animal) as previously re-
ported (20, 22). After infection, animals were monitored daily for clinical
signs of FMD. Symptoms included vesiculation in the tongue, mouth, and
feet, lameness, increased salivation, loss of appetite, and fever (rectal tem-
perature above 39.5°C).
Vaccines, vaccinations, and inactivated FMDV antigens. To assess
local FMDV-specific ASC in the respiratory tract of vaccinated cattle be-
fore and after infection, 14 animals received one dose of a single-oil-
emulsion monovalent vaccine containing 23.5 g of inactivated FMDV
O1/Campos strain per dose, kindly provided by Biogénesis-Bagó S.A. (Ar-
gentina). Two additional naive animals (326 and 370) as well as 3 multi-
vaccinated bovines (177, 231, and 232), all utilized in the B-cell memory
assays, were vaccinated with a commercial tetravalent FMD single-oil-
emulsion vaccine, including the O1/Campos strain. In all cases, animals
were injected with a 2-ml vaccine dose applied intramuscularly in the neck
(left side).
Inactivated and concentrated suspensions of FMDV O1 Campos also
were provided by Biogénesis-Bagó S.A., and 140S viral particles for in vitro
experiments were purified by following a sucrose density gradient centrif-
ugation method optimized in our laboratory as previously published (22).
Experimental design and sampling. Fourteen animals receiving the
monovalent O1/Campos strain FMD vaccine were used to assess the ex-
istence of local FMDV-specific ASC prior to (n  4) and after (n  10)
aerosol infection with the homologous strain at 30 days postvaccination
(dpv). Two vaccinated animals were euthanized and necropsied at times
before infection (7 and 29 dpv) and then at 2, 3, 4, 5, and 6 days postin-
fection (dpi). Heparinized whole-blood and serum samples were collected
from the jugular vein of all surviving animals at 0, 7, 21, and 29 dpv and
daily between days 2 and 6. Also, at each time starting at 7 dpv, different
lymphoid organs were obtained postmortem from each animal: left pres-
capular lymph node (PSL), mandibular lymph nodes (ML), medial and
lateral retropharyngeal lymph nodes (MRL and LRL, respectively), pha-
ryngeal tonsil (PhT), tracheobronchial lymph nodes (TBL), and spleen
(SP). All lymphoid organs were collected aseptically and placed in ice-cold
wash buffer (RPMI 1640, 10 mM HEPES, 106 U/ml penicillin G sodium,
700 mg/ml streptomycin, and 500 mg/ml gentamicin) until processing.
The remaining two naive animals were utilized in the memory B-cell
experiments and sampled for heparinized blood and serum at 30 days
after primary vaccination. Animals were euthanized and prescapular,
mandibular, and tracheobronchial lymph nodes also were procured from
these animals at that same time postvaccination. All three multivaccinated
animals were sampled for heparinized blood 4 days after the last revacci-
nation.
Purification of MNC. Mononuclear cell (MNC) suspensions were ob-
tained from lymphoid tissues as previously described (22). Peripheral
blood MNC (PBMC) were isolated from heparinized whole-blood sam-
ples and centrifuged at 800  g for 20 min at 4°C. Buffy coats were col-
lected and seeded on top of Ficoll Histopaque solutions (1,083 g/ml; BD,
New Jersey, USA) and centrifuged at 800  g for 45 min at 20°C by
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following the manufacturer’s instructions. Finally, cell suspensions were
washed 2 times and pellets were resuspended in complete medium (wash
buffer with 10% bovine fetal serum), and their viability was determined by
trypan blue exclusion (95%).
Serology assays. Neutralizing antibodies were detected by a micro-
plate virus neutralization assay modified in our laboratory (22). Neutral-
izing antibody titers were expressed as the TCID50 neutralized by the
diluted serum samples (1:32) according to the Reed and Muench method
(23). Isotype profiles of FMDV-specific bovine antibodies were deter-
mined by an indirect ELISA according to Capozzo et al. (24), except that
sheep-anti-bovine IgG1 and IgG2 horseradish peroxidase (HRP)-conju-
gated antibodies were used (1:750) and sheep anti-bovine IgM HRP-con-
jugated antibody (1:5000) was used (BD-Serotec, Oxford, United King-
dom). Isotype antibody titers were expressed as the highest dilution of the
serum reaching an optical density (OD) equal to the mean OD obtained
from 25 negative sera 2 standard deviations (SD).
FMDV-specific ASC detection. Anti-FMDV ASC were detected by
means of a virus-specific ASC-enzyme-linked immunosorbent spot
(ELISPOT) assay as previously reported (22). Spots corresponding to ASC
were visualized and enumerated manually under a stereomicroscope, and
results were expressed as the mean numbers  standard errors of the
means (SEM) of FMDV-specific ASC per 5  105 total MNC in triplicate
wells.
FMDV-specific memory B-cell detection. To study the presence of
FMDV-specific memory B cells in peripheral blood and lymph nodes,
MNC suspensions from these tissues were incubated for 6 days under
culture conditions promoting the polyclonal differentiation of mem-
ory B lymphocytes into ASC cells while leading to the depletion of
preexisting ASC. This step was followed by the detection of FMDV-
specific ASC by ELISPOT assay. Differentiation of memory B cells into
plasma B cells was performed as described by Grant et al. (25), with
minor modifications. Briefly, MNC suspensions were incubated in T25
flasks (1  106 cells/ml) for 6 days with complete medium enriched
with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential
amino acids, and 50 M -mercaptoethanol and containing a mixture
of pokeweed mitogen (5 g/ml; Sigma), recombinant human interleu-
kin-2 (IL-2; 20 ng/ml; Meridian Life Science Inc.), recombinant bo-
vine IL-10 (2,200 IU/ml; Kingfisher Biotech Inc.), and anti-bovine
CD40 monoclonal antibody (MAb) (2 g/ml; ILA-158), kindly pro-
vided by Brian Charleston. In parallel, cultures without the stimulat-
ing cocktail were run as negative controls. After 6 days, MNCs from
both stimulated and nonstimulated cultures were harvested, washed,
and seeded onto nitrocellulose plates in sextuplicate wells coated with
purified inactivated FMDV O1/Campos (10 g/well) diluted in phos-
phate-buffered saline (PBS) (pH 7.5) or with PBS alone. From this
stage on, the FMDV-specific ASC detection was performed as de-
scribed above, except that the assay was revealed only with mouse
anti-bovine IgG1 MAb (BD-Serotec, Oxford, United Kingdom). Re-
sults for each animal were expressed as the mean number of ASC in
wells with the purified FMDV, corrected by subtraction of the mean
ASC counts from the corresponding wells without the viral antigen.
FMDV RNA quantification. The presence of FMDV genomic RNA in
serum samples taken daily from oronasally infected cattle was assessed by
a real-time quantitative RT-PCR (qRT-PCR), performed as previously
described (22). PCR primers and standard plasmid carrying the FMDV
3D target sequence were kindly provided by Guido König.
Statistical analysis. Differences in mean FMDV-specific serum iso-
type titers at different time points and differences in the mean number of
total ASC produced per isotype at different time points and with different
organs were analyzed by two-way analysis of variance (ANOVA), and pair
comparisons were carried out using a Bonferroni posttest. Analyses were
performed using Graph Pad Prism 5.0 software (Graph Pad Software
Inc.).
RESULTS
Progression of systemic adaptive antibody responses in FMDV-
vaccinated cattle before and after experimental oronasal infec-
tion. To analyze the progression of the systemic and local antibody
response in FMDV-vaccinated cattle, 14 steers were intramuscularly
immunized with a single-oil-emulsion vaccine comprised of 23.5 g/
dose of inactivated FMDV strain O1/Campos. Furthermore, 10 of
them were infected with the homologous virus by the oronasal
route at 30 dpv. All animals developed a solid protective immune
response. None of the vaccinated and challenged animals showed
symptoms of the disease between 2 and 6 dpi (n  10), and ac-
cordingly, FMDV RNA could not be detected by qRT-PCR in any
of the serum samples obtained between 1 and 6 dpi.
The development of systemic antibody responses in these ani-
mals was measured by different means. Circulating FMDV-neu-
tralizing antibodies were measured before vaccination and at 7,
21, and 29 dpv in all surviving animals. Mean antibody titers
reached 4.48  103  1.91  103 TCID50 neutralized within 7 days
after vaccination (n  14) and then remained within titers of 103
to 104 TCID50 neutralized up to 29 dpv. Oronasal infection did not
significantly modify neutralizing antibody titers, actually showing
a slight decrease toward 6 dpi (Fig. 1).
The maturation of the systemic antiviral antibody response
also was assessed in terms of the immunoglobulin isotype compo-
sition. The isotype profiles of circulating antibodies before and
after aerosol infection are shown in Fig. 2. One week after vacci-
nation, the highest titers were obtained from the IgM subclass,
followed by IgG1 and then IgG2 (P  0.0001 in both cases). Three
weeks after vaccination, all antibody titers increased and a switch
in the isotype profile was evident with mean IgG1 titers signifi-
cantly above those of IgM and IgG2 (P  0.0004 and P  0.0024,
respectively).
Just before oronasal infection, isotype profiles presented a very
similar pattern, with mean IgG1 titers higher than those of IgM
and IgG2 (P  0.0089 in both cases). Interestingly, time course
and isotype progression detected in FMD-vaccinated individuals
resembled those already described by our group (22) for naive
animals after oronasal infection with virulent FMDV (Fig. 2), ex-
cept that IgG1 switch in infected animals could be verified earlier
than that in vaccinated cattle, and IgG2 titers remained signifi-
FIG 1 Time course of virus-neutralizing antibodies in FMD vaccinated cattle
before and after oronasal FMDV infection. Naive cattle were immunized with
a monovalent FMDV O1/Campos vaccine and further infected by aerosolized
FMDV (107 TCID50 per animal) at 30 dpv (indicated by an arrow). Serum
samples were obtained at 0, 7, 21, and 29 dpv and between 1 and 6 days
postinfection. Systemic antibody responses are expressed as mean numbers of
TCID50 neutralized by the diluted sera (1:32) from all surviving animals at each
time  standard errors of the means.
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cantly below those for IgM and IgG1 for at least 2 weeks in naïve
infected individuals. One day after oronasal infection, a significant
decrease in mean antibody titers (which lasted at least until day 5
pi) was evident for IgG1 (P  0.026) and IgM (P  0.0017) but not
for IgG2 (Fig. 2). These titers remained unaltered until day 4 post-
challenge.
These results indicate that humoral responses elicited after sys-
temic FMD vaccination shared similarities to those already re-
ported for the oronasal FMDV infection (22) in terms of time
course and progression of the isotype profiles. Subsequent orona-
sal infection of the vaccinated steers did not result in disease, but it
was followed by a slight drop in neutralizing antibody titers, which
was correlated with a transient decrease in IgM and IgG1 FMDV-
specific antibodies.
Mucosal adaptive antibody responses in FMDV-vaccinated
cattle before and after oronasal infection. The assessment of a
local FMDV-specific antibody response occurring along the respi-
ratory tract of vaccinated cattle was accomplished by detecting the
presence of mucosal antibody-producing B cells by ASC-
ELISPOT assay. The assay was performed at early (7 dpv) and late
(29 dpv) times postvaccination and after oronasal infection with
the homologous virus (n  2 at each time). As is shown in Fig. 3,
systemic vaccination elicited a rapid and strong stimulation in the
PSL ipsilateral to the immunization site (255  155 ASC/5  105
total MNC), which increased almost two times in magnitude at 29
dpv (503  17.5 ASC/5  105 total MNC). Interestingly, several
lymphoid tissues draining the respiratory mucosa (ML, MRL, and
LRL) revealed the presence of low but significant numbers of
FMDV-specific ASC at 7 dpv. This phenomenon was somewhat
enhanced in magnitude and expanded to all lymphoid tissues at 29
dpv, even to those such as TBL, which were far from the inocula-
tion site. Therefore, parenteral immunization induced the early
presence of FMDV-specific antibody responses in the respiratory
tract that was sustained and extended at least up to 29 dpv.
The predominance of PSL also was observed soon after orona-
sal infection (2 dpi). Starting at 3 dpi, however, the mean number
FIG 2 Isotypes of FMDV-specific serum antibodies in FMD-vaccinated cattle before and after oronasal FMDV infection. Each line corresponds to a particular
isotype, and each point represents the average ELISA titer obtained for all animals assayed. Titers are expressed as the highest dilution of the serum reaching an
OD value equal to 0.2 (mean value from 25 negative sera  2 SD). The time point for the oronasal infection is indicated by a gray arrow. For comparative
purposes, isotype profiles obtained from naïve infected animals (previously published [22]) are shown as dotted lines. Significant differences in mean antibody
titers are the following: a and b, IgM  IgG1 and IgM  IgG2 (P  0.0001 in both cases) at 7 dpv, respectively; c and e, IgG1  IgM at 21 (P  0.0024) and 29
dpv (P  0.0089), respectively; d and f, IgG1  IgG2 at 21 (P  0.0004) and 29 dpv (P  0.0089), respectively; g, IgM at 29 dpv  IgM at 1 dpi (P  0.0017); h,
IgG1 at 29 dpv  IgG1 at 1 dpi (P  0.026).
FIG 3 Detection of FMDV-specific antibody-secreting cells in lymphoid or-
gans of the respiratory tract from vaccinated and further infected cattle. Pres-
capular (PSL) and mandibular lymph nodes (ML), pharyngeal tonsils (PhT),
lateral (LRL) and medial retropharyngeal lymph nodes (MRL), tracheobron-
chial lymph nodes (TBL), and spleen (S) from FMD-vaccinated bovines were
processed and assayed by the FMDV-ASC ELISPOT assay at 7 and 29 dpv and
between 2 and 6 days postoronasal infection. Results are expressed as the
number of FMDV-specific ASC per 5  105 extracted MNC, and each bar
represents the average value for 2 individuals  standard errors of the means.
Significant differences in mean ASC numbers/5  105 total MNC were the
following: a, PSL  ML, MRL, LRL, PhT, TBL, and S (P  0.05) at 29 dpv; b,
PSL  ML, MRL, LRL, PhT, TBL, and S (P  0.01) at 2 dpi; c, TBL  PSL, ML,
LRL, and PhT (P  0.001) at 5 dpi; d, TBL  S (P  0.01) at 5 dpi; e, MRL 
PSL, ML, LRL, and PhT (P  0.05) at 6 dpi; and f, TBL  PSL, ML, MRL, LRL,
PhT, and S (P  0.001) at 6 dpi.
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of FMDV-specific ASC in this tissue declined, while at the same
time an increasing stimulation of some of the lymphoid tissues
draining the respiratory system also was evident (Fig. 3). Total
anti-FMDV ASC in TBL increased 	42 times between 3 and 6
days after infection. Five days after infection, the mean number of
FMDV-specific ASC in TBL (draining the lower respiratory tract)
were significantly above those of PSL, ML, LRL, PhT, and SP (P 
0.01), and 1 day later, TBL ASC counts were higher than those of
all the other tissues studied (P  0.001) (Fig. 3). Similarly, mean
anti-FMDV ASC counts in MRL (draining the upper respiratory
tract) were raised 	25 times from 3 to 6 dpi, and they were signif-
icantly higher than those in the remaining tissues studied, except
for TBL, at 6 dpi (P  0.05) (Fig. 3). The spleen also exhibited a
rise in the total amount of FMDV-specific ASC from 3 to 6 dpi (an
approximately 20-fold increase). The remaining lymphoid tissues
from the respiratory tract (ML, LRL, and PhT) did not show sig-
nificant variations in total ASC numbers after oronasal infection.
Thus, the entrance of the challenge virus into the respiratory sys-
tem stimulated the rapid growth of the preexisting vaccine-in-
duced local antibody response, involving lymph nodes which
drain early replication sites described for the virus entering
through the aerogenous route (9).
Immunoglobulin isotype profiles of the local adaptive
FMDV-specific antibody responses in cattle after FMD vaccina-
tion and further oronasal infection of vaccinated animals. We
next studied the isotype composition of anti-FMDV-specific an-
tibody responses localized in lymphatic tissues using the ASC-
ELISPOT assay. Seven days after vaccination, IgM was the domi-
nant isotype among anti-FMDV ASC in PSL (205.3  92.4 ASC/
5  105 MNC), significantly above the level of IgG1 (P  0.001)
(Fig. 4A). FMDV-specific ASC from IgG2 or IgA isotypes could
not be detected at this time. Similarly, the low number of FMDV-
specific ASC observed in other lymphoid tissues at this time
mostly corresponded to IgM-secreting cells.
Just before oronasal infection (Fig. 4B), a class switch was clear
in PSL, suggesting anti-FMDV IgG1 ASC counts (395.3  18.9)
were significantly greater than those of IgM and IgG2 (P  0.001).
Again, IgA ASC were undetectable. At the same time, most of
FIG 4 Isotype profiles of the anti-FMDV ASC developed in vaccinated cattle before and after FMDV aerosol exposure. Mononuclear cells were purified from the
same lymphoid tissues as that described in the legend to Fig. 3 and assayed by the FMDV-ASC ELISPOT assay using monoclonal (IgG1 and IgG2) or polyclonal
(IgM and IgA) antibodies against bovine immunoglobulin isotypes as probes. Each panel (A to G) represents a particular time point, and results are expressed
as described in the legend to Fig. 3 for each particular isotype and organ. Lowercase letters above each bar indicate significant differences with other isotypes in
the same tissue and time point (Table 1).
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the anti-FMDV ASC within the lymphoid organs related to the
respiratory system consisted of IgM-producing B lymphocytes
(Fig. 4B).
Soon after aerosol infection (2 dpi), isotype profiles displayed
patterns similar to those prior to the challenge, except for lym-
phoid tissues draining the respiratory tract, which also showed
low levels of IgG1 and IgA FMDV-specific ASC (Fig. 4C). Starting
3 days postinfection, the first changes were evident. Mean IgG1
levels in PSL at 3 dpi were significantly lower than those at 29 dpv
(P  0.001), and they remained below the ASC counts observed
before vaccination (P  0.001 for all times), with a slight but
constant decrease up to 6 dpi (Fig. 4B).
Progression of anti-FMDV IgG1 ASC responses were the op-
posite in TBL. From 3 dpi, the average number of IgG1-producing
cells in this tissue augmented daily (P  0.001) to reach a mean
value of 778  17.9 ASC/5  105 MNC at 6 dpi, significantly above
the rest of the organs and higher than that of the other isotypes in
TBL at that time (P  0.001) (Fig. 4D to G and 5B). A similar
observation for IgG1, but starting after 4 dpi, also could be de-
tected in MRL and spleen, reaching mean IgG1 ASC values of
292  16.4 and 221  98.8 ASC/5  105MNC, respectively (Fig.
4E to G and 5B). The other lymphoid tissues assayed (ML, LRL,
and PhT) also seemed to experience a proliferation of IgG1-secret-
ing cells but at a much lower magnitude and only after 5 dpi (Fig.
4G). FMDV-specific IgG2-secreting lymphocytes also increased
their mean values from 4 to 5 dpi in TBL and MRL (P  0.001 and
P  0.01, respectively) and from 5 to 6 dpi exclusively in TBL (P 
0.001). Significantly, IgM-secreting cells augmented their counts
daily between 4 and 6 dpi exclusively in TBL and MRL (P  0.001
and P  0.01) (Fig. 5A). Consequently, IgM ASC in these two
tissues were second in magnitude, above IgA and IgG2 ASC at 5
dpi and 6 dpi (Fig. 4F and G and Table 1). Once again, FMDV-
specific IgA-secreting cells (Fig. 5D) did not demonstrate signifi-
cant variations after aerosol infection, except for a slight increase
in TBL from 4 to 5 dpi (P  0.01) and from 5 to 6 dpi (P  0.001).
Table 1 comprises a full description of the significant differences
found in the mean number of FMDV-specific ASC among iso-
types for each organ and time point assayed.
These experiments support an independent development of
the anti-FMDV antibody responses occurring near the vaccina-
tion site, mostly coincident with the serum antibodies, and those
taking place at distal lymphoid tissues, both before and after oro-
nasal infection. Moreover, vaccine-induced immunity in distal
lymph nodes consisted of active antibody-secreting B cells but also
other resting B lymphocytes which were activated in large num-
bers to locally produce FMDV-specific ASC after aerosol infec-
tion.
Detection of FMDV-specific memory B cells in FMD-vacci-
nated cattle. In an effort to identify the origin of the ASC locally
detected in the respiratory tract after vaccination, the presence of
FMDV-specific memory B lymphocytes was assayed in MNC
from PSL, ML, or TBL or peripheral blood obtained from animals
FIG 5 Effect of the oronasal infection on the time course of FMDV-specific ASC in different lymphoid tissues from FMD-vaccinated cattle. Each panel presents
the time progression of the mean anti-FMDV ASC counts for each particular isotype. Tissues and results are expressed as described in the legend to Fig. 3. Arrows
indicate the oronasal infection time point. Selected significant differences in mean FMDV-specific ASC numbers/5  105 total MNC are represented in
each graph as letters in lowercase. (A) a, TBL and MRL levels at 4 dpi were lower than those at 5 dpi (P  0.001); b, S at 4 dpi  5 dpi (P  0.05); c, TBL
and S at 5 dpi  6 dpi (P  0.001); d, MRL at 5 dpi  6 dpi (P  0.01). (B) e, TBL at 4 dpi  5 dpi (P  0.001); f, MRL at 4 dpi  5 dpi (P  0.05); g, TBL
at 5 dpi  6 dpi (P  0.001); h, S at 4 dpi  6 dpi (P  0.01). (C) i, TBL at 4 dpi  5 dpi (P  0.001); j, MRL at 4 dpi  5 dpi (P  0.01); k, TBL at 5 dpi 
6 dpi (P  0.001). (D) l, TBL at 4 dpi  5 dpi (P  0.01); m, TBL at 5 dpi  6 dpi (P  0.001).
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immunized with a commercial FMD vaccine. To this end, MNC
suspensions from these tissues were incubated for 6 days under
culture conditions promoting the depletion of ASC already pres-
ent and the polyclonal differentiation of preexisting memory B
cells into ASC, followed by the detection of FMDV-specific ASC
by ELISPOT assay. Primo-vaccinated animals (n  2) were tested
at 30 dpv. Both animals had high antibody titers against FMDV
O1/Campos by LPB-ELISA (data not shown). However, neither of
these steers presented significant numbers of anti-FMDV ASC as a
result of the differentiation from FMDV-specific memory B cells
in any of the tissues assayed.
In order to maximize the chance of finding circulating FMDV-
specific memory B cells, we repeated the experiment but used
multivaccinated animals (n  3) and performed the determina-
tion in peripheral blood 4 days after revaccination. In this case, all
multivaccinated animals were consistently positive for FMDV-
specific memory B cells in circulating blood but had low mean
numbers: 8.4  1.2 (animal 177), 14.6  2.0 (animal 231), and
14.0  4.5 (animal 232) per 5  105 total MNC. These results
indicate that FMD vaccination effectively induces the presence of
FMDV-specific memory B cells, although at a very low frequency.
DISCUSSION
Correlates of the immunity generated by FMD vaccines and pro-
tection against FMDV infections in cattle traditionally have been
established based on the presence of specific serum antibody titers
above defined thresholds. Such cutoff values are particular for
each strain and were calculated from correlations involving large
numbers of animals, combining results of in vivo challenge tests
and in vitro serology assays (26, 27). This concept, however, di-
minishes the importance of other relevant aspects of immunity,
such as the respiratory mucosal response that may play an impor-
tant role during aerogenous FMDV infection in cattle.
In this work, systemic immunization with a high-payload
monovalent FMD vaccine elicited neutralizing antibody kinetics
and patterns of immunoglobulin isotypes resembling those ob-
served after oronasal FMDV infection in naive individuals. Fol-
lowing a sharp increase during the first week postvaccination,
neutralizing antibody titers reached a plateau that was maintained
until 30 dpv. Accordingly, all animals exhibited a solid protection
to the oronasal challenge performed at that time, showing neither
symptoms of the disease nor detectable viremia. Interestingly, the
slight reduction in mean neutralizing antibody titers observed af-
ter infection coincided with a significant decrease, 1 day after in-
fection, in the mean titers of FMDV-specific IgM and IgG1, while
IgG2 titers remained unchanged. On the one hand, this indicates
that at least in some of the animals, circulating antibodies might
have found virulent virus administered by the oronasal route. On
the other hand, these observations are concurrent with previous
findings by our group and others regarding the potential in vivo
FMDV-neutralizing roles for the bovine IgM in naive cattle at
early times postinfection (22) and the IgG1 isotype in vaccinated
animals at later times postimmunization (24, 28).
Most significantly, we described for the first time that, besides
the systemic and ASC responses in the draining lymph node, in-
tramuscular (systemic) FMD vaccination in the neck also was ca-
pable of promoting local virus-specific ASC in respiratory lym-
phoid tissues in cattle. The detailed follow up of these coexisting
adaptive responses, occurring in different sites but all initiated by
the intramuscular vaccination, revealed differences between the
local and systemic immunity and supported the idea of indepen-
dent pathways in the antibody responses occurring near the vac-
cination site, mostly coincident with the serum antibodies, and
those taking place at distal lymphoid tissues placed along the re-
spiratory tract. The first of these differences was the important
variation in the isotype composition observed from 7 to 29 dpv in
the draining lymph node ASC and the systemic antibody re-
sponses compared to the rather invariant response, both in mag-
nitude and isotype profile, registered in the distal lymph tissue
ASC between 7 and 29 dpv.
One of the hypotheses to explain the existence of FMDV-spe-
cific ASC in lymphoid tissues distant from the vaccination spot is
the local presence of vaccine viral antigen, alone or associated with
antigen-presenting cells (29), and migration from the immuniza-
tion site to stimulate the generation of ASC in situ. Our attempts to
detect vaccine-derived antigens failed to demonstrate their exis-
tence in mandibular and tracheobronchial lymph nodes from vac-
cinated bovines at 30 dpv. Crude extracts from these organs ren-
dered negative results (data not shown) for genome detection by
PCR, capsid protein detection by immunoassays, and immuniza-
tion experiments. The inoculation of tissue extracts in mice after
waning of the primary immune response was induced by 50 ng of
inactivated FMDV O1/Campos in PBS to detect secondary anti-
FMDV responses by an indirect ELISA (29). While we cannot rule
out the occurrence of virus antigen below the detection thresh-
olds, the modest increase in magnitude and lack of significant
changes in the isotype composition of the FMDV-specific ASC in
these lymph nodes between 7 and 29 dpv were compatible with the
absence of vaccine-derived viral antigens in these tissues. In con-
trast, ASC responses of the PSL at the vaccination spot, exposed to
persisting antigen stimulation, underwent a significant isotype
switch mainly toward IgG1 antibodies at 29 dpv.
Interestingly, oronasal infection in the vaccinated animals re-
vealed additional differences between both types of responses.
Further aerogenous infection, the early changes in isotype com-
position, and rapid increases in magnitude of the antibody re-
sponses triggered in the local respiratory lymph nodes, especially
in TBL and MRL, contrasted with the lack of major modifications
and the slow waning of the ASC responses in the draining PSL.
Hence, it was evident that vaccine-induced immunity in distal
lymph nodes not only consisted of active antibody-secreting B
cells but also included other resting B lymphocytes which were
activated in secondary lymphoid tissues to locally produce
FMDV-specific ASC upon aerosol infection. Such immune reac-
tions started around 3 to 4 days postinfection and followed closely
the early tissue replication pattern already described for aeroge-
nous FMDV infections in naive cattle (9). Also notably, these B-
cell memory responses lead to a marked predominance of IgG1
ASC from 4 dpi but also to a significant growth in the IgM ASC
counts in these organs, being the second isotype in magnitude
from 4 to 6 dpi. These IgM-producing cells also could have re-
sulted from the activation of new clones by the virulent FMDV
entering the respiratory tract, as in naive animals, although we do
not have direct evidence to support this hypothesis.
Our results do not allow us to determine the exact origin of the
FMDV-specific B cells in distal lymph nodes. Nevertheless, the
detection of circulating memory B cells in multivaccinated cattle,
albeit at very low frequencies, suggests that these cells originated at
the site of inoculation. Antigen-specific memory B cells can be
retained in draining lymphoid sites together with follicular Th
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cells after subcutaneous protein immunization (30), and recircu-
lation of antigen-specific B lymphocytes has been demonstrated
after primo-vaccination with other immunogens in mice and hu-
mans. Conjugate polysaccharide-protein vaccine antigens carry-
ing T-cell-dependent and -independent antigenic determinants,
as described for whole FMDV particles (31, 32), are able to gener-
ate antibody responses and transient memory B cells in nasopha-
ryngeal mucosa after systemic immunization in humans (33, 34).
Other reports also showed that circulating antigen-specific B cells,
some of which were memory B cells expressing surface markers
enabling their recirculation to secondary lymphoid organs, also
could be detected within 7 to 10 days following systemic immuni-
zation in mice (35, 36). It also is possible that memory B lympho-
cytes generated after local immunization can be recalled with a
local challenge at a distal site in the presence of an inflammatory
stimulus, permitting their entry into resting lymph nodes, from
where they usually are excluded (37). Even when we cannot con-
firm any of these possibilities, the previous literature indicates that
such mechanisms actually exist in other animal models, sharing
similarities with our present observations.
These results provide new evidence and a more comprehensive
understanding of the immune responses elicited in cattle by the
existing inactivated FMD vaccines, offering new insights and pos-
ing questions about the actual mechanisms put in place in vacci-
nated bovines to prevent the development of the disease after
aerogenous infection. It is worth noting that each time point de-
termination for FMDV-specific ASC was performed on a different
pair of bovines, and despite this potential source of variation, time
course progressions for each isotype and organ proved to remain
consistent, overcoming potential physiological and genetic differ-
ences among individuals. As a whole, our results indicate that
FMD vaccination in cattle result in the circulation of virus-specific
B lymphocytes, including memory B cells that differentiate to ASC
soon after contact with the infective virus in secondary lymphoid
tissues. Among others, an interesting aspect of this study is to
investigate whether the magnitude of these local memory B-cell
responses can be used as a correlate of the protective efficacy for
new vaccines under development.
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